Have you become addicted to Zolpidem without awareness that there are severe Zolpidem Withdrawals? Have you tried to get off Zolpidem only to have serious insomnia that you restarted Zolpidem? Are you wondering, "How long does Zolpidem withdrawal last?" Do you want help to do a proper Zolpidem Taper while helping to calm through a holistic approach? We know you need relief to get off Zolpidem and that is why for 15 years we have helped people in 78 countries to ease their Zolpidem Withdrawal symptoms naturally while they gradually do a Zolpidem Taper. It is possible to Taper off Zolpidem and it is possible to regain natural sleep patterns. If you slept before Zolpidem then you can sleep again. Our nonprofit believes in a slow, at-home Zolpidem Taper with natural relief that works. We guide each client individually for correct Zolpidem taper rates and teach you about Zolpidem interactions that make withdrawal more challenging. Let our nonprofit guide you out of Zolpidem Withdrawal. CONTACT us for a FREE consultation.*
Our Zolpidem weaning program is a slow taper that allows you to safely step down from Zolpidem under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Zolpidem until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Zolpidem withdrawal and support well-being*
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Zolpidem Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; goals; and interactions. Don't Wean Zolpidem alone, work with our Prescription Drug Experts.*
Imagine being Free of Zolpidem Dependency
- Proven Program completed In-Home with Expert Guidance
- Slowly Taper Zolpidem
- All-Natural Nutraceuticals to Help Ease Zolpidem Withdrawal*
- Professional Information on Interactions
- Free Mentoring on our 24/7 Private Discussion Board
- Free Assessment Upon Starting our Program (a $400 value)
Enter Discount Code SleepingPillFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only
ZOLPIDEM WITHDRAWAL SUCCESS STORIES
"I am proud of my accomplishment, completely and entirely due to you, your team and your program." More...
Dene H. (Zolpidem Withdrawal Success Story)
"I tapered successfully off of Zolpidem and today I am entirely drug-free and I fall asleep every night!" More...
Bianca (Zolpidem Withdrawal Success Story)
"I am now drug free! I sleep better than ever, and I am back as good as new, with a few extra miles." More...
Alex (Zolpidem Withdrawal Success Story)
"I simply cannot recommend Point of Return highly enough for people whose bodies have become dependent on medication(s). They know, they understand and they are there to help you." More...
Joel (Zolpidem Withdrawal Success Story)
"Thank you Point of Return for your never ending words of encouragement, advice, love and new found friendship. I am forever grateful to all of you." More...
Becky (Zolpidem Withdrawal Success Story)
"By utilizing the experienced, capable, and highly informed assistance available through Point of Return I have enabled my body, mind and spirit to recuperate. Point of Return's effective nutritional products alongside their unsurpassed support have given me a second chance." More...
Trudee (Zolpidem Withdrawal Success Story)
God put you on my life's Master Plan as His agent to restore and change my life and arrive at my Point of Return. Indeed I have arrived! I am truly grateful! More...
—Nomusa (Zolpidem Withdrawal Success Story)
EXPERIENCE and TEAMWORK
using a Natural Approach
ZOLPIDEM HISTORY AND INFORMATION
Zolpidem (Ambien) was launched in 1992 for the treatment of insomnia and subsequently the DEA classified Zolpidem as safe compared to Halcion, which had demonstrated serious concerns. The danger of Zolpidem surfaced when reports of night driving or eating, strange behavior and addiction were reported at an alarming rate. Zolpidem should only be used short term due to the risk of tolerance, drug dependence, rebound insomnia and central nervous system related adverse effects. Once tolerance to the sleeping pill has occurred it is recommended to do a gradual dose reduction to minimize symptoms that resemble benzodiazepine withdrawal.
Sales hit $1.8 billion by 2005 and Ambien (Zolpidem)was prescribed 40 million times in 2011 alone. The patent expired and the FDA approved thirteen generic forms of Zolpidem.
In 2001 Peter Buck (guitarist for R.E.M) went crazy on a British Airlines flight and nearly went to jail – he blamed Ambien (Zolpidem). In 2006 Patrick Kennedy, driving on Ambien (Zolpidem) had a terrible auto crash that made headlines. Shortly after, the FDA added multiple warnings on Ambien's (Zolpidem) label stating that the drug did cause people to drive, have sex or eat food without remembering. In 2013 the FDA lowered the dosage recommendations in half for Ambien (Zolpidem) for women stating, "blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving."
The number of emergency room visits involving adverse reactions to Zolpidem have jumped 220% in a five year period, according to SAMHSA (Substance Abuse and Mental Health Services Administration). 74% of the patients were age 45 or older and 68% were women. The adverse reactions include daytime drowsiness, dizziness, hallucinations, agitation, sleep-walking, strange behavior without awareness and daytime drowsiness.
Zolpidem is classified as a nonbenzodiazepine hypnotic however its effects are similar to those of benzodiazepines. And while Zolpidem showed effectiveness in initiating sleep, it did not adequately demonstrate effectiveness in maintaining sleep.
Zolpidem binds to a subtype of the GABA receptor. GABA is a neurotransmitter that primarily works to inhibit the activity of neurons and calm nerves. It basically counters too much stimulation on the nervous system. When Zolpidem binds to the GABA receptor, it slows and stops activity in certain parts of the brain thus its classification as a hypnotic. Zolpidem diminishes activity in parts of the brain that are responsible for processing thoughts. As tolerance to the drug occurs the nervous system become hyper-stimulated, increasing anxiety, insomnia, pain, cognitive impairment, and other symptoms.
Zolpidem should only be used short term due to the risk of tolerance, drug dependence, rebound insomnia and central nervous system related adverse effects.
Once tolerance to the sleeping pill has occurred it is recommended to do a gradual dose reduction to minimize symptoms that resemble benzodiazepine withdrawal.
ZOLPIDEM WITHDRAWAL SYMPTOMS, SIDE EFFECTS, ADVERSE REACTIONS
ZOLPIDEM WITHDRAWAL SYMPTOMS MAY INCLUDE:
abdominal pains, aching, agoraphobia, anxiety, blurred vision, body vibrations, changes in perception, diarrhea, distended abdomen, feeling of unreality, flu-like symptoms, flatulence, food cravings, hair loss, heart palpitations, heavy limbs, increased allergies, increased sense of smell, insomnia, lethargy, loss of balance, metallic taste, muscle spasms, nightmares, panic attacks, paranoia, persistent & unpleasant memories, severe headaches, shaking, short term memory loss, sore mouth and tongue, sound & light sensitivity, speech difficulties, sweating, suicidal thoughts, tinnitus, unusually sensitive, fear, dysphoria, fatigue, nausea, lightheadedness, uncontrolled crying, emesis
ZOLPIDEM SIDE EFFECTS MAY INCLUDE:
allergy, daytime drowsiness, dizziness, drugged feeling, headache, indigestion, nausea, difficulty with coordination, memory loss, tolerance, dependency, changes in behavior and thinking, more outgoing, strange behavior, agitation, worsening of depression, suicidal thoughts, abdominal pain, abnormal dreams, abnormal vision, amnesia, anxiety, arthritis, back pain, bronchitis, burning sensation, chest pain, confusion, constipation, coughing, daytime sleeping, decreased mental alertness, depression, diarrhea, difficulty breathing, difficulty concentrating, difficulty swallowing, diminished sensitivity to touch, dizziness on standing, double vision, dry mouth, emotional instability, exaggerated feeling of well-being, eye irritation, falling, fatigue, fever, flu-like symptoms, gas, general discomfort, hallucination, hiccup, high blood pressure, high blood sugar, increased sweating, infection, insomnia, itching, joint pain, lack of bladder control, lack of coordination, lethargy, light-headedness, loss of appetite, menstrual disorder, migraine, muscle pain, nasal inflammation, nervousness, numbness, paleness, prickling or tingling sensation, rapid heartbeat, rash, ringing in the ears, sinus inflammation, sleep disorder, speech difficulties, swelling due to fluid retention, taste abnormalities, throat inflammation, throbbing heartbeat, tremor, unconsciousness, upper
ZOLPIDEM ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: visual impairment, pulmonary embolism, ventricular tachycardia, pulmonary edema, myocardial infarction, arrhythmia exacerbation, anaphylactic shock, angioedema, GI obstruction, bronchospasm, renal failure, azotemia, thrombosis, bone fractures, intracranial bleeding, suicidal ideation, laryngeal edema, anaphylactoid reactions, hepatic encephalopathy
Moderate: hallucinations, amnesia, memory impairment, depression, palpitations, constipation, blurred vision, conjunctival hyperemia, impaired cognition, hypertension, chest pain, orthostatic hypotension, sinus tachycardia, edema, dysphagia, dyspenea, vainitis, dysuria, cystitis, urinary incontinence, hyperglycemia, elevated hepatic enzymes, dysarthria, migraine, hypotension, angina, phlebitis, furunculosis, bullous rash, gastritis, hemorrhoids, myashtenia, conjunctivitis, photopsia, hypoxia, urinary retention, impotence, gout, hyperlipidemia, hypercholesterolemia, hyperbilirubinemia, anemia, lymphadenopathy, leukopenia, hot flashes, tetany, tolerance, confusion, euphoria, ataxia, complex sleep-related behaviors, respiratory depression, erythema, oral ulceration, jaundice, withdrawal, psychological dependence, physiological dependence
Mild: dizziness, headache, drowsiness, nausea, malaise, back pain, myalgia, sinusitis, fatigue, lethargy, anxiety, xerostomia, diarrhea, influenza, psychomotor impairment, rash, arthralgia, muscle cramps, abnormal dreams, nightmares, agitation, syncope, pallor, hyperhidrosis, pruritus, urticaria, anorexia, vomiting, dysgeusia, gastroesophageal reflux, flatulence, infection, fever, pharyngitis, tinnitus, occular irritation, occular pain, rhinitis, cough, menorrhagia, vaginal irritation, hypoesthesia, parethesias, emotional lability, tremor, flushing, photosensitivity, acne vulgaris, hypersalivation, eructation, dental caries, tenesmus, weight loss, restless legs syndrome, chills, lacrimation, epistaxis, laryngitis, mastalgia, nocturia, increased urinary frequency, polyuria, purpura, libido decrease, yawning, appetite stimulation, hiccups, dyspepsia, asthenia, diplopia, vertigo, insomnia, somnambulism, abdominal pain
ZOLPIDEM BOXED WARNINGS: per PDR
Coadministration with other CNS depressants, complex sleep-related behaviors, driving or operating machinery, drug-induced complex sleep-related behaviors, ethanol ingestion
Sedative-hypnotics can cause complex sleep-related behaviors such as phone calls, sexual activity, preparing and eating food, or sleep driving while not fully awake and in some cases having no memory of the event. These behaviors appear to be more frequent with nonbenzodiazepine benzodiazepine-receptor agonists (NBRAs), such as zolpidem, than other sedative-hypnotics. Although rare, serious injuries or death have occurred; therefore, zolpidem and other NBRAs are contraindicated in patients with a history of drug-induced complex sleep-related behaviors. Patients should be informed of the risks before receiving any medication from this class, including instructions to discontinue the medication if they experience a sleep-related episode and to contact their healthcare provider immediately. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of NBRAs to the FDA MedWatch Safety Information and Adverse Event Reporting Program. Because zolpidem has a rapid onset of action and causes CNS depressant activity, zolpidem products indicated for insomnia due to difficulty with sleep initiation should only be administered immediately before retiring and with at least 7 to 8 hours remaining before the planned time of waking. Zolpidem products indicated for difficulty returning to sleep after middle-of-the-night awakenings should only be taken while the patient is in bed and has at least 4 hours of bedtime remaining before the planned time of waking. Vehicle drivers and machine operators should be warned that hypnotics, such as zolpidem, have a possible risk of adverse reactions including drowsiness, prolonged reaction time, dizziness, sleepiness, blurred/double vision, reduced alertness and impaired driving, even the day after use. Patients should be instructed to avoid driving or operating machinery or performing other tasks requiring mental alertness for at least 8 hours after taking immediate-release formulations, and patients receiving the extended-release formulation should be alerted about the potential impact on such activities the full day after use. Patients receiving zolpidem for middle-of-the-night awakenings should wait for at least 4 hours after dosing and until they feel fully awake before driving or engaging in other activities requiring full mental alertness. Because zolpidem can cause drowsiness and a decreased level of consciousness, there is a higher risk of falls, particularly in the elderly, with the potential for subsequent severe injuries. Zolpidem use has been associated with severe injuries such as hip fractures and intracranial hemorrhage. Due to gender differences in the elimination of zolpidem, a lower initial dose is recommended in adult females (women). Plasma levels of zolpidem in some patients, particularly women, may be high enough the morning after use to impair activities requiring mental alertness, such as driving. The risk for next-morning impairment is higher if zolpidem products are taken without adherence to the proper hours for sleep recommended following use or if a higher than the recommended dose is taken. Risks for impairment are also increased during coadministration with other CNS depressants with zolpidem or with use of drugs that increase the blood levels of zolpidem. Concurrent alcohol or CNS depressant use increases the risk for CNS depression, impairment, complex sleep-related behaviors, and other additive effects. Patients taking zolpidem should avoid ethanol ingestion. Lower initial dosages of zolpidem should be considered in patients taking other CNS-depressant therapies. Anterograde amnesia may be particularly evident at zolpidem doses above 10 mg/day.
ZOLPIDEM REFERENCES AND OTHER INTO
PER THE FDA
Following the rapid dose decrease or abrupt discontinuation of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs [see Drug Abuse and Dependence (9)].
Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.
Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, and convulsions. The following adverse events which are considered to meet the DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal were reported during U.S. clinical trials following placebo substitution occurring within 48 hours following last zolpidem treatment: fatigue, nausea, flushing, lightheadedness, uncontrolled crying, emesis, stomach cramps, panic attack, nervousness, and abdominal discomfort. These reported adverse events occurred at an incidence of 1% or less. However, available data cannot provide a reliable estimate of the incidence, if any, of dependence during treatment at recommended doses. Post-marketing reports of abuse, dependence and withdrawal have been received.
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
* Testimonial results may vary person to person.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..